SCHEMBL16090164

SCHEMBL16090164

CCNc1ncnc(C)c1C

nearest known ligand 0.43

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 1/20 0.43
POLB P06746 1/20 0.39
SMN1; SMN2 Q16637 2/20 0.38
MEN1 O00255 1/20 0.38
LMNA P02545 1/20 0.38
RAF1 P04049 1/20 0.38
KMT2A Q03164 1/20 0.38
SIRT2 Q8IXJ6 1/20 0.37
MAP4K4 O95819 2/20 0.36
CD38 P28907 1/20 0.35
GRM1 Q13255 1/20 0.33
PGK1 P00558 1/20 0.33
HTT P42858 1/20 0.33
PDE10A Q9Y233 1/20 0.33
ALDH1A1 P00352 1/20 0.33
CHRM4 P08173 1/20 0.32
FFAR2 O15552 1/20 0.32
ADORA3 P0DMS8 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20130427 0.83 POLB (0.56) KDM4EPOLBSMN1; SMN2MEN1LMNA
SCHEMBL16090155 0.80 POLB (0.35) KDM4EPOLBSMN1; SMN2MEN1LMNA
SCHEMBL20130428 0.80 TLR8 (0.53) KDM4EPOLBSMN1; SMN2MEN1LMNA
SCHEMBL21416115 0.79 KDM4E (0.41) KDM4EPOLBSMN1; SMN2MEN1LMNA
SCHEMBL23895417 0.78 TSHR (0.43) POLBSMN1; SMN2MEN1LMNARAF1
SCHEMBL25509455 0.78 CYP1A2 (0.44) POLBSMN1; SMN2MEN1LMNARAF1
SCHEMBL15715717 0.75 KDM4E (0.38) KDM4EPOLBSMN1; SMN2MEN1LMNA
SCHEMBL14983681 0.75 YTHDC1 (0.44) KDM4EPOLBMEN1LMNAKMT2A
SCHEMBL22048110 0.73 MEN1 (0.38) KDM4ESMN1; SMN2MEN1LMNAKMT2A
SCHEMBL19957830 0.71 CRHR1 (0.36) POLBSMN1; SMN2MEN1LMNARAF1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10258698-B2 Formulation and delivery of modified nucleoside, nucleotide, and nucleic acid compositions MODERNATX, INC. (US) 2019-04-16 US disclosed
US-20180125937-A1 MODIFIED NUCLEOSIDE, NUCLEOTIDE, AND NUCLEIC ACID COMPOSITIONS MODERNATX, INC. (US) 2018-05-10 US disclosed
WO-2016044641-A2 CARM1 INHIBITORS AND USES THEREOF Epizyme, Inc. (US) 2016-03-24 WO disclosed
WO-2014144169-A1 CARM1 INHIBITORS AND USES THEREOF Epizyme, Inc. (US) 2014-09-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180125937-A1 MODIFIED NUCLEOSIDE, NUCLEOTIDE, AND NUCLEIC ACID COMPOSITIONS NSUN2, RNMT, NSUN3 KDM4E 4406/4885POLB 139/4885SMN1; SMN2 171/4885
US-10258698-B2 Formulation and delivery of modified nucleoside, nucleotide, and nucleic acid compositions NSUN2, RNMT, ADAR KDM4E 4437/4885POLB 180/4885SMN1; SMN2 131/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.